Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Mar 20;40(9):978-987.
doi: 10.1200/JCO.21.02006. Epub 2022 Jan 7.

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)

Seema A Khan  1 , Fengmin Zhao  2 , Lori J Goldstein  3 , David Cella  4 , Mark Basik  5 , Mehra Golshan  6 , Thomas B Julian  7 , Barbara A Pockaj  8 , Christine A Lee  9 , Wajeeha Razaq  10 , Joseph A Sparano  11 , Gildy V Babiera  12 , Irene A Dy  13 , Sarika Jain  1 , Paula Silverman  14 , Carla S Fisher  15 , Amye J Tevaarwerk  16 , Lynne I Wagner  17 , George W Sledge  18
Affiliations
Randomized Controlled Trial

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)

Seema A Khan et al. J Clin Oncol. .

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] J Clin Oncol. 2022 Apr 20;40(12):1392. doi: 10.1200/JCO.22.00666. J Clin Oncol. 2022. PMID: 35427466 Free PMC article. No abstract available.

Abstract

Purpose: Distant metastases are present in 6% or more of patients with newly diagnosed breast cancer. In this context, locoregional therapy for the intact primary tumor has been hypothesized to improve overall survival (OS), but clinical trials have reported conflicting results.

Methods: Women presenting with metastatic breast cancer and an intact primary tumor received systemic therapy for 4-8 months; if no disease progression occurred, they were randomly assigned to locoregional therapy for the primary site (surgery and radiotherapy per standards for nonmetastatic disease) or continuing sysmetic therapy. The primary end point was OS; locoregional control and quality of life were secondary end points. The trial design provided 85% power to detect a 19.3% absolute difference in the 3-year OS rate in randomly assigned patients. The stratified log-rank test and Cox proportional hazards model were used to compare OS between arms. Cumulative incidence of locoregional progression was compared using Gray's test. Quality-of-life assessment used standard instruments.

Results: Of 390 participants enrolled, 256 were randomly assigned: 131 to continued systemic therapy and 125 to early locoregional therapy. The 3-year OS was 67.9% without and 68.4% with early locoregional therapy (hazard ratio = 1.11; 90% CI, 0.82 to 1.52; P = .57). The median OS was 53.1 months (95% CI, 47.9 to not estimable) in the systemic therapy arm and 54.9 months (95% CI, 46.7 to not estimable) in the locoregional therapy arm. Locoregional progression was less frequent in those randomly assigned to locoregional therapy (3-year rate: 16.3% v 39.8%; P < .001). Quality-of-life measures were largely similar between arms.

Conclusion: Early locoregional therapy for the primary site did not improve survival in patients presenting with metastatic breast cancer. Although it was associated with improved locoregional control, this had no overall impact on quality of life.

Trial registration: ClinicalTrials.gov NCT01242800.

PubMed Disclaimer

Conflict of interest statement

Lori J. GoldsteinStock and Other Ownership Interests: CureVacHonoraria: Daiichi Sankyo, Roche/Genentech, Amgen, Mylan, Merck, Eisai, Immunomedics, Exact SciencesConsulting or Advisory Role: Genentech, Genomic Health, Merck, Mylan, Immunomedics, Amgen, Eisai, Exact SciencesResearch Funding: Merck (Inst), Genentech/Roche (Inst)Other Relationship: Daiichi Sankyo David CellaStock and Other Ownership Interests: FACIT.orgConsulting or Advisory Role: AbbVie, GlaxoSmithKline, Pfizer, Astellas Pharma, Novartis, Bristol Myers Squibb, Asahi Kasei, Ipsen, Mei PharmaResearch Funding: Novartis (Inst), Ipsen (Inst), Pfizer (Inst), PledPharma (Inst), Bristol Myers Squibb (Inst), AbbVie (Inst), Regeneron (Inst), Clovis Oncology (Inst) Mark BasikHonoraria: Roche CanadaResearch Funding: Pfizer, LabCorp Mehra GolshanConsulting or Advisory Role: AbbVie, BertisResearch Funding: Breast Cancer Research Foundation Christine A. LeeConsulting or Advisory Role: OlympusSpeakers' Bureau: AstraZeneca/Merck, OncoCyte Joseph A. SparanoStock and Other Ownership Interests: MetaStatConsulting or Advisory Role: Genentech/Roche, Novartis, AstraZeneca, Celgene, Lilly, Celldex, Pfizer, Prescient Therapeutics, Juno Therapeutics, Merrimack, Adgero Biopharmaceuticals, Cardinal Health, Pfizer, GlaxoSmithKline, CStone Pharmaceuticals, Epic Sciences, Daiichi Sankyo, BMSiSpeakers' Bureau: Eisai, CertaraResearch Funding: Prescient Therapeutics (Inst), Deciphera (Inst), Genentech/Roche (Inst), Merck (Inst), Novartis (Inst), Novartis (Inst), Merrimack (Inst), Radius Health (Inst), Olema Pharmaceuticals (Inst)Travel, Accommodations, Expenses: Menarini Silicon Biosystems, Roche/Genentech, Adgero Biopharmaceuticals, Myriad Genetics, Pfizer, AstraZeneca, Rhenium Medical Gildy V. BabieraStock and Other Ownership Interests: PolyPidHonoraria: Insightec, GleolanConsulting or Advisory Role: Insightec, Gleolan, Theracal, Polypid, NektarPatents, Royalties, Other Intellectual Property: Patent Holder for DNX 2401 and DNX2440 Owned by DNAtrixTravel, Accommodations, Expenses: Gleolan, Insightec Sarika JainEmployment: G1 TherapeuticsStock and Other Ownership Interests: G1 Therapeutics Carla S. FisherConsulting or Advisory Role: Biom'UpTravel, Accommodations, Expenses: Biom'Up Amye J. TevaarwerkOther Relationship: Epic Systems Lynne I. WagnerStock and Other Ownership Interests: Johnson & Johnson, Lilly, Gilead SciencesConsulting or Advisory Role: Celgene, AthenexTravel, Accommodations, Expenses: Celgene George W. SledgeLeadership: Syndax, Tessa TherapeuticsStock and Other Ownership Interests: Syndax, Tessa Therapeutics, PionyrConsulting or Advisory Role: Symphogen, Synaffix, Syndax, Verseau Therapeutics, GRAIL, AstraZeneca, G1 TherapeuticsResearch Funding: Genentech/Roche (Inst), Pfizer (Inst)Travel, Accommodations, Expenses: Verseau Therapeutics, Tessa TherapeuticsNo other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
CONSORT diagram shows the progression of patients through the study. Per protocol, only those showing stable or responsive disease after optimal systemic therapy were randomly assigned to the two arms. Results were presented at the American Society of Clinical Oncology Annual Meeting in June 2020.
FIG 2.
FIG 2.
Kaplan-Meier plots of (A) OS and (B) locoregional progression, comparing the systemic therapy arm with the early locoregional therapy arm, among patients who demonstrated stable or responsive disease after initial systemic therapy and were randomly assigned. (C) Health-related quality of life as measured by the FACT-B TOI Score. HR, hazard ratio; OS, overall survival; TOI, Trials Outcome Index. If breast cancer is diagnosed after distant spread has occurred, surgery and radiation for the breast tumor do not improve survival.
See this image and copyright information in PMC

Comment in

References

    1. Agarwal G, Pradeep PV, Aggarwal V, et al. Spectrum of breast cancer in Asian women World J Surg 311031–10402007 - PubMed
    1. Siegel RL, Miller KD, Jemal A.Cancer statistics, 2020 CA Cancer J Clin 707–302020 - PubMed
    1. Norton L, Massague J.Is cancer a disease of self-seeding? Nat Med 12875–8782006 - PubMed
    1. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis Nature 449557–5632007 - PubMed
    1. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 3451655–16592001 - PubMed

Publication types

Associated data